"给公司取名'泰坦'，就是冲着希腊神话里巨人敢扛敢闯的劲儿，想在科学服务领域闯出新路。"谢应波 笑着说，创业后没空打游戏，但一点点磨技能、攒经验直至通关的"进阶劲儿"没丢。"我们心怀成就伟 业的抱负，希望做一家不辜负青春年华、受人尊重的企业。" 从"造自行车"到"造飞机" "经过多年在科学服务行业摸爬滚打，像泰坦科技这样的本土企业，手里早已攥满优质技术和产品，可 真要打破国外品牌'卡脖子'的局面，还需要产业能级的'纵身一跃'。"谢应波一语点透行业进阶的核心痛 点。 谢应波介绍，公司近些年聚焦产业能级建设这一件事，把原先顶多算"造自行车"的制造能级，迭代升级 为"造飞机"，力求打破行业发展的天花板，让本土产品也能撑得起高端场景。 泰坦科技累计服务超过6万家客户、100万科研人员，其中世界500强客户超150家，全国研发型生物医药 企业的覆盖率更是突破八成。 ◎记者 王墨璞嘉 曾长期困于海外技术垄断、受制于产业基础薄弱的国内科学服务行业，如今正迎来本土企业突围的澎湃 浪潮。这场"科学服务突围战"的关键破局者，正是泰坦科技。 从2007年萌芽于华东理工大学宿舍的大学生创业项目，到2020年登陆科创板成为"科学服务第 ...

浦江蜿蜒，润泽上海多个产业园区；浪涛汹涌，击打出创新的节拍；货轮远航，驶向广阔的国际市 场……"十五五"规划建议擘画出未来五年的战略蓝图，一批上海科创公司为国担当、勇为尖兵，瞄准创 新与国际化"双线突围"，谋篇布局高质量发展。 硬核创新是扎根本土的底气。上海完善的科创生态，为企业攻坚"卡脖子"技术提供了肥沃土壤。乘着上 海支持创新创业的东风，80后的大学生创业者谢应波带领泰坦科技，在科学服务行业闯出一条国产化之 路；从生物材料到生物制造，凯赛生物手握颠覆性创新技术，大胆挺进合成生物产业蓝海；面对"数据 危机"带来的挑战，英方软件接连翻越研发、市场与信任"三座山"，以硬实力打造数据"保险栓"；20年 精耕细作，从3G到6G，创远信科不断夯实通信测试技术底座，用"工业之尺"刻画着产业新高度。 开放布局是链接全球的桥梁。依托上海国际科创中心的优势，科创企业家不约而同将未来五年的发展目 光投向国际市场。凯赛生物董事长刘修才说，公司要成为世界生物制造产业的开拓者，并培养中国生物 制造的同路人。在泰坦科技的"征途墙"上，董事长谢应波为"十五五"之路贴上了一个新的关键词 ——"出海"。面对海外客户对中国基础软件的偏见，英方 ...

Core Viewpoint - Titan Technology has established a smart production base in Yichang, Hubei, which represents a significant shift in China's scientific service industry, moving from reliance on imported reagents and equipment to a strong domestic presence [1][2]. Company Development - Titan Technology was founded by a group of university students aiming to provide better services for laboratories, focusing on the reliability of reagents and equipment [2][3]. - The company received initial funding of 200,000 yuan from the Shanghai University Student Science and Technology Entrepreneurship Fund, which has supported numerous entrepreneurial projects since its inception in 2006 [2]. Business Strategy - The company has shifted its strategy from merely pursuing scale to focusing on profitability, with a significant increase in the sales and gross margin of its proprietary brands [4][5]. - In 2024, the sales revenue from proprietary brands accounted for 63.23% of total sales, with a gross margin of 84.74%, indicating a strong competitive position in the market [4]. Mergers and Acquisitions - Titan Technology has actively pursued mergers and acquisitions to expand its proprietary brand portfolio, completing acquisitions of three companies and establishing two joint ventures in 2024 [5][6]. - The acquisition of Anhui Tiandi High-Purity Solvent Co., Ltd. significantly increased its production capacity from 3,800 tons to 13,800 tons after modernization [5]. Product Development - The company has launched new high-end scientific instruments, such as the IVScope8000Pro small animal imaging system, and developed gold standard chromatographic solvents, which have received positive market feedback [6][7]. - The gold standard chromatographic solvents have been upgraded to significantly reduce impurities, meeting or exceeding the standards of imported brands [6]. Digital Transformation - Titan Technology emphasizes digitalization and modeling in its operations to enhance efficiency and reduce costs, including the development of an intelligent warehousing and logistics system [7][8]. - The company has implemented a full inventory QR code digital management system, improving inventory management efficiency and traceability [7]. Future Outlook - The smart production base is designed to operate with minimal human intervention, utilizing advanced AI algorithms for real-time data analysis and predictive maintenance, which will enhance product quality and operational efficiency [8].

Core Viewpoint - The announcement highlights the launch of the IVScope8000Pro small animal in vivo imaging system by Titan Technology's subsidiary, showcasing the company's advancements in high-end optical instruments and its potential impact on the market [1][2]. Group 1: New Product Overview - The IVScope8000Pro is a high-end research instrument developed independently, featuring a high-precision optical system design that overcomes several key technical bottlenecks [1]. - The product ensures consistency in multi-channel fluorescence signals, allowing for precise quantification of fluorescence experimental data [1]. - Key performance indicators of the product meet the standards of international imported products, making it a significant tool in biomedical research for drug development, disease mechanism studies, and gene therapy [1]. Group 2: Impact on the Company - The successful development of the IVScope8000Pro demonstrates the subsidiary's technological innovation capabilities in the high-end scientific instrument sector [2]. - The product enriches the company's proprietary brand instrument product line and enhances its product matrix in the life sciences instrument segment [2]. - The company has already received some overseas customer orders and domestic procurement intentions, which are expected to positively influence market expansion, replacement of imported brands, and overall performance growth [2].